Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | APEX1 | P27695 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283818 | 0.83 | HMGCR (0.53) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL13225464 | 0.82 | TAAR1 (0.50) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL14283785 | 0.81 | PDE4A (0.52) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL2736890 | 0.80 | TAAR1 (0.55) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL12629209 | 0.80 | TAAR1 (0.46) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL2908279 | 0.79 | HMGCR (0.50) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL29063428 | 0.79 | MAPT (0.52) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL69624 | 0.79 | MAOB (0.59) | HMGCRTSHRTAAR1MAPK1LMNA | |
| SCHEMBL19685198 | 0.79 | MEN1 (0.55) | MAPK1LMNANFKB1CYP3A4MEN1 | |
| SCHEMBL1754342 | 0.79 | TRPV1 (0.48) | HMGCRTSHRTAAR1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0526302-B1 | Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica | OREAL (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0526302-A1 | Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica | L'OREAL (FR) | 1993-02-03 | — | — | EP | claimed |
| US-8552013-B2 | Heterocyclic compounds based on N6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2013-10-08 | — | — | US | disclosed |
| US-8505730-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120312717-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8273791-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-7816350-B2 | Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2010-10-19 | — | — | US | disclosed |
| EP-1348707-B1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | USTAV EX BOTAN AV CR V V I I O (CZ) | 2010-08-25 | — | — | EP | disclosed |
| EP-2087880-A2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | Jr Chem, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080014227-A1 | HETEROCYCLIC COMPOUNDS BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2008-01-17 | — | — | US | disclosed |
| US-7279482-B2 | Heterocyclic compound based on N6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | Ústav experimentálni botaniky Akademie ved Ceské republiky (CZ) | 2007-10-09 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
| US-6960347-B2 | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | L'OREAL (FR) | 2005-11-01 | — | — | US | disclosed |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) | 2005-02-24 | — | — | US | disclosed |
| CN-1556808-A | Based on N6Heterocyclic compounds of substituted adenine, process for their preparation, their use for the preparation of medicaments, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | �ݿ˹�����������ʵ��ֲ��ѧ�� | 2004-12-22 | — | — | CN | disclosed |
| EP-1348707-A1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) | 2003-10-01 | — | — | EP | disclosed |
| US-20010036446-A1 | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | L'OREAL (FR) | 2001-11-01 | — | — | US | disclosed |
| EP-0526302-B1 | Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica | OREAL (FR) | 1995-03-01 | — | — | EP | disclosed |
| EP-0526302-A1 | Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica | L'OREAL (FR) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014227-A1 | HETEROCYCLIC COMPOUNDS BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | TYMP, CCNB1, CCNA2 | HMGCR 1561/4885TSHR 1108/4885TAAR1 2142/4885 |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ATIC, UMPS, CCNB1 | HMGCR 1888/4885TSHR 1625/4885TAAR1 3350/4885 |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | RARG, RARA, RXRG | HMGCR 814/4885TSHR 2502/4885TAAR1 4868/4885 |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | HMGCR 2674/4885TSHR 2431/4885TAAR1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.